SHIRIN MOBEEN: Open Payments
NPI 1265069652 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$746 in 23 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $267 · 2025 $746
Food & beverage: $746
| Company | Payments | Amount |
|---|---|---|
| Celltrion USA Inc. | 7 | $297 |
| Gilead Sciences, Inc. | 1 | $114 |
| ABBVIE INC. | 5 | $88 |
| Janssen Biotech, Inc. | 3 | $66 |
| Lilly USA, LLC | 2 | $51 |
| Ardelyx, Inc. | 2 | $46 |
| Novo Nordisk Inc | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
Products named: VEGZELMA, ZYMFENTRA, Livdelzi, TREMFYA, CREON, OMVOH, IBSRELA, LINZESS.
Industry payments across FL — which companies pay providers there.
